Results 221 to 230 of about 5,027,565 (330)

Development and validation of early-stage and progression prediction models for chronic kidney disease: a retrospective study. [PDF]

PeerJ
Wan T, Chen Q, Gao Y, Luo R, Li N, Feng Y.   +5 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Radiotherapy for the management of bone metastases in differentiated thyroid cancer. [PDF]

Clin Transl Radiat Oncol
Faulkner C, Mesci A, Alfadli F, Brierley JD, Tsang R, Ye XY, Mete O, Ma L, Barron C, Krzyzanowska MK, Lukovic J.   +10 more
europepmc   +1 more source

MicroRNA-1 suppresses tumor progression and UHRF1 ex-pression in cholangiocarcinoma

Muto, Makoto
openalex   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Patients' responses & reflections when receiving news of cancer progression: a qualitative study. [PDF]

BJC Rep
Ten Hove J, Kain D, Galica J, O'Donnell J, Brundage MD.   +4 more
europepmc   +1 more source

Bifunctional TRPV1 Targeted Magnetothermal Switch to Attenuate Osteoarthritis Progression

Zhongyang Lv, Peng Wang, Weitong Li, Ya Xie, Wei Sun, Xiaoyu Jin, Ruiyang Jiang, Yuxiang Fei, Yuan Liu, Tianshu Shi, Hu Guo, Ziying Sun, Jintao Lin, Xucai Wang, Guihua Tan, Yizhang Wu, Nirong Bao, Dongquan Shi   +17 more
openalex   +1 more source

Mathematical models of mechanisms underlying long-term type 2 diabetes progression

, 2012
Erica J. Graham
openalex   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. [PDF]

BMJ Open
Hong SH, Lee H, Lee SY, Sung YA, Hong YS, Song DK, Jung H, Kim MH.   +7 more
europepmc   +1 more source